Exabis Library
Welcome to the e-CCO Library!
P351: Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P351: Faecal calprotectin correlates well with extent of active endoscopic inflammation in patients with ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P351: MRI outcomes in perianal fistulising Crohn’s disease following anti-TNF-α therapy: a systematic review and meta-analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P351: SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn’s disease: single tertiary center experience
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P351: Validation of anterior thigh ultrasound for screening of sarcopenia and elevated body fat in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P352 Infliximab-therapy intensification based on endoscopic activity suppresses treatment interruption among patients with Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P352: A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P352: Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P352: Is diagnostic delay associated with the risk of colectomy in patients with ulcerative colitis? Results of a study of the Austrian IBD study group
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P352: Melanoma in a population-based Australian inflammatory bowel disease cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P352: Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P352: TDM of infliximab in IBD-patients: which pharmacokinetic marker to use?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P352: Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P353 Assessing compliance to screening for infectious diseases and vaccination in patients newly diagnosed with inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P353: Aberrant brain structural large-scale connectome in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P353: Agreement between patients, senior and junior physicians on disease activity and burden scoring in inflammatory bowel disease, using a tele-monitoring platform
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P353: Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea: An update
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P353: Endoscopy-based management within the first year after surgery decreases the risk of clinical and surgical postoperative recurrences in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P353: Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P353: Pan-enteric capsule endoscopy enables assessment of mucosal healing after biologic treatment initiation in Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM